ArriVent BioPharma financials
$29.54+0.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$52.7M | -$46.1M | -$38.8M | -$38.3M | -$33.6M | -$66.8M | -$23.7M | -$24.2M | -$25.7M | -$20.7M |
| Net income | -$49.9M | -$43.3M | -$35.5M | -$35.0M | -$31.4M | -$64.4M | -$20.6M | -$20.6M | -$21.9M | -$17.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.05 | $-0.96 | $-0.83 | $-0.83 | $-0.90 | $-1.90 | $-0.61 | $-0.61 | $-0.65 | $-0.70 |
| EBITDA | -$52.7M | -$46.7M | -$41.8M | -$38.3M | -$33.6M | -$66.8M | -$23.7M | -$24.2M | -$25.7M | -$20.7M |
| Operating cash flow | $0.00 | -$41.9M | -$30.7M | -$35.8M | $0.00 | -$68.0M | -$16.2M | -$16.3M | -$19.1M | -$18.6M |
| Free cash flow | $0.00 | -$41.9M | -$30.7M | -$35.8M | $0.00 | -$68.0M | -$16.2M | -$16.3M | -$19.1M | -$18.6M |
| Diluted shares | 47.6M | 45.1M | 43.0M | 41.9M | 35.0M | 33.9M | 33.7M | 33.6M | 33.5M | 25.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $154.7M | $62.1M | $45.5M | $112.7M | $112.8M | $49.9M |
| Short-term investments | $218.4M | $264.3M | $267.3M | $187.6M | $122.9M | $126.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $394.7M | $349.3M | $333.2M | $326.6M | $269.5M | $215.5M |
| Total liabilities | $27.9M | $25.3M | $25.9M | $21.6M | $19.6M | $13.0M |
| Shareholders' equity | $366.8M | $324.0M | $307.2M | $305.0M | $249.9M | $202.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology